Prognoza
Średnia cena docelowa analityków wynosi 18,23 € (+1485,22%). Mediana wynosi 18,23 € (+1485,22%).
| Kupuj |
3 |
| Trzymaj |
2 |
| Sprzedaj |
0 |
Dyskusje w społeczności
Nie ma jeszcze dyskusji o tym aktywie.
Rozpocznij dyskusjęWiadomości Przejdź do aktualności
Aligos Therapeutics presents two-pillar strategy against hepatitis B with pevifoscorvir and ALG‑170675
At the Cantor Fitzgerald Healthcare Conference, Aligos Therapeutics unveiled an HBV strategy combining pevifoscorvir (a capsid-assembly modulator) for chronic suppression with the antisense oligonucleotide ALG‑170675 as a route toward functional cure. Pevifoscorvir showed high potency, good oral bioavailability and sustained S-antigen reduction in phase‑I data; a phase‑II superiority study versus tenofovir was expanded after an interim analysis did not meet the futility threshold. ALG‑170675 has entered clinical development in China and is intended to show additive to synergistic effects in combination with pevifoscorvir, substantially enlarging the addressable patient population. Further progress depends on ongoing clinical data and regulatory steps. » Więcej na de.investing.com
Aligos Therapeutics rises 7.6% premarket after sustained positive momentum
Aligos Therapeutics shares climbed 7.6% in premarket trading to $6.55, despite no company-specific news that day. The move was driven by continued positive sentiment following strong Q2 results showing a significantly smaller net loss and an EPS beat, and by non-dilutive funding from a licensing agreement for Pevifoscorvir sodium in China. In addition, full patient recruitment for the Phase-2 B-SUPREME study was completed, reducing pipeline risk. The outperformance came despite weaker U.S. indices, and the stock remains well below its 52-week high of $13.69. » Więcej na de.investing.com
Aligos completes patient recruitment for phase‑2 study B‑SUPREME
Aligos has completed recruitment for both parts of the phase‑2 B‑SUPREME study of pevifoscorvir sodium in chronic hepatitis B (131 HBeAg‑positive in part 1a, 114 HBeAg‑negative in part 2a). The larger participant number in part 1a made a second interim sample‑size analysis unnecessary. The stock rose 13% on the news last week but is down 29% year‑to‑date; the company has a market capitalization of USD 41 million and more cash than debt. Key safety and efficacy data are expected in late Q3 2027. » Więcej na de.investing.com
Aligos Therapeutics receives $25m upfront payment for Greater China license, shares rise
Aligos Therapeutics received an upfront payment of $25 million from Xiamen Amoytop for an exclusive license to Pevifoscorvir sodium for the treatment of chronic HBV infections in Greater China. In addition, up to $420 million in milestone payments and tiered royalties in the high single-digit percentage range were agreed. The payment is likely to extend the cash runway into the fourth quarter of 2026, while Aligos retains commercial and development rights outside Greater China and the right to conduct clinical trials in the region. The announcement drove the share price up nearly 20% in after-hours trading. » Więcej na de.investing.com
Licensing deal with Amoytop sends Aligos Therapeutics stock higher
Aligos Therapeutics granted an exclusive license for pevifoscorvir sodium to Xiamen Amoytop Biotech for Greater China and received a $25 million upfront payment. The deal includes up to $420 million in milestone payments and tiered royalties. Aligos retains rights for the U.S., Europe, South Korea, Japan and other markets, may run studies in Greater China, and Amoytop will fund the program there. The transaction is expected to extend Aligos’ cash runway into Q4 2026 and prompted a roughly 20% share price increase. » Więcej na de.investing.com
Dane finansowe
W ostatnim kwartale Aligos Therapeutics Aktie osiągnęła przychody w wysokości 2,53 mln € i zysk netto w wysokości -19,3 mln €
| (EUR) | wrzesień 2026 | YoY |
|---|---|---|
| Przychody | 2,53 mln | 301,14% |
| Zysk brutto | 2,53 mln | 301,14% |
| Zysk netto | -19,3 mln | 28,19% |
| EBITDA | -19,01 mln | 27,52% |
Dane fundamentalne
| Wskaźnik | Wartość |
|---|---|
Kapitalizacja rynkowa | 8,09 mln € |
Liczba akcji | 6,25 mln |
Maksimum/minimum z 52 tygodni | 12,48 € - 1,11 € |
| Dywidendy | Nie |
Beta | 2,42 |
C/Z (PE Ratio) | -0,22 |
PEG (PEG Ratio) | 0,00 |
C/WK (PB Ratio) | 1,31 |
C/S (PS Ratio) | 0,26 |
Profil spółki
| Nazwa | Aligos Therapeutics Aktie |
| CEO | Lawrence Blatt |
| Pracownicy | 82 |